Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections

References

• Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001 May 3;344(18):1378–1388. PubMed PMID: 11333996 .
   PubMed Web of Science ®Google Scholar
• van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000 Jan;13(1):144–66, table of contents. PubMed PMID: 10627495; PubMed Central PMCID: PMC88937.
   PubMed Web of Science ®Google Scholar
• Lewis LA, Ram S. Meningococcal disease and the complement system. Virulence. 2014 Jan 1;5(1):98–126. PubMed PMID: 24104403; PubMed Central PMCID: PMC3916388.
   PubMed Web of Science ®Google Scholar
• Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013 Apr;19(4):566–573. PubMed PMID: 23628376; PubMed Central PMCID: PMC3647402.
   PubMed Web of Science ®Google Scholar
• Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Iimmunol. 2006 Jul 01;177(1):501–510. PubMed PMID: 16785547; PubMed Central PMCID: PMC2248442.
   PubMed Web of Science ®Google Scholar
• Lewis LA, Ngampasutadol J, Wallace R, et al. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 2010 Jul 29;6(7):e1001027. PubMed PMID: 20686663; PubMed Central PMCID: PMC2912398.
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Pajon R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccin Immunother. 2012 Feb;8(2):174–183. PubMed PMID: 22426368. .
   PubMed Web of Science ®Google Scholar
• McCarthy PC, Sharyan A, Sheikhi Moghaddam L. Meningococcal vaccines: current status and emerging strategies. Vaccines (Basel). 2018 Feb 25;6(1):12. PubMed PMID: 29495347; PubMed Central PMCID: PMC5874653.
   PubMed Web of Science ®Google Scholar
• Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991 Jul;4(3):359–395. PubMed PMID: 1889047; PubMed Central PMCID: PMC358203.
   PubMed Web of Science ®Google Scholar
• Klos A, Tenner AJ, Johswich KO, et al. The role of the anaphylatoxins in health and disease. Mol Immunol. 2009 Sep;46(14):2753–2766. PubMed PMID: 19477527; PubMed Central PMCID: PMC2725201.
   PubMed Web of Science ®Google Scholar
• Jagels MA, Daffern PJ, Hugli TE. C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology. 2000 Mar;46(3):209–222. PubMed PMID: 10741901.
   PubMed Web of Science ®Google Scholar
• Albrecht EA, Chinnaiyan AM, Varambally S, et al. C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol. 2004 Mar;164(3):849–859. PubMed PMID: 14982839; PubMed Central PMCID: PMC1613300.
   PubMed Web of Science ®Google Scholar
• Monsinjon T, Gasque P, Chan P, et al. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. Faseb J. 2003 Jun;17(9):1003–1014. PubMed PMID: 12773483.
   PubMed Web of Science ®Google Scholar
• Hawlisch H, Wills-Karp M, Karp CL, et al. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol. 2004 Jun;41(2–3):123–131. PubMed PMID: 15159057.
   PubMed Web of Science ®Google Scholar
• Strey CW, Markiewski M, Mastellos D, et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med. 2003 Sep 15;198(6):913–923. PubMed PMID: 12975457; PubMed Central PMCID: PMC2194207.
   PubMed Web of Science ®Google Scholar
• Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature. 1991 Feb 14;349(6310):614–617. PubMed PMID: 1847994.
   PubMed Web of Science ®Google Scholar
• Ward PA. The harmful role of C5a on innate immunity in sepsis. J Innate Immun. 2010;2(5):439–445. PubMed PMID: 20588003; PubMed Central PMCID: PMC2968761.
   PubMed Web of Science ®Google Scholar
• Arumugam TV, Magnus T, Woodruff TM, et al. Complement mediators in ischemia-reperfusion injury. Clin Chim Acta. 2006 Dec;374(1–2):33–45. PubMed PMID: 16872589.
   PubMed Web of Science ®Google Scholar
• Johswich K, Martin M, Bleich A, et al. Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. Inflamm Bowel Dis. 2009 Dec;15(12):1812–1823. PubMed PMID: 19714742.
   Google Scholar
• Monk PN, Scola AM, Madala P, et al. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol. 2007;152(4):429–448.
   PubMed Web of Science ®Google Scholar
• Köhl J. Drug evaluation: the C5a receptor antagonist PMX-53. Curr Opin Mol Ther. 2006 Dec;8(6):529–538. PubMed PMID: 17243489.
   PubMedGoogle Scholar
• Okinaga S, Slattery D, Humbles A, et al. C5L2, a nonsignaling C5A binding protein. Biochemistry. 2003 Aug 12;42(31):9406–9415. PubMed PMID: 12899627.
   PubMed Web of Science ®Google Scholar
• Scola AM, Johswich KO, Morgan BP, et al. The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol. 2009 Mar;46(6):1149–1162. PubMed PMID: 19100624; PubMed Central PMCID: PMC2697321.
   PubMed Web of Science ®Google Scholar
• Gerard NP, Lu B, Liu P, et al. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem. 2005 Dec 02;280(48):39677–39680. PubMed PMID: 16204243.
   PubMed Web of Science ®Google Scholar
• Wang R, Lu B, Gerard C, et al. C5L2, the second C5a anaphylatoxin receptor, suppresses LPS-induced acute lung injury. Am J Respir Cell Mol Biol. 2016 Nov;55(5):657–666. PubMed PMID: 27285858; PubMed Central PMCID: PMC5105183.
   PubMed Web of Science ®Google Scholar
• Rittirsch D, Flierl MA, Nadeau BA, et al. Functional roles for C5a receptors in sepsis. Nat Med. 2008 May;14(5):551–557. PubMed PMID: 18454156; PubMed Central PMCID: PMC2753858.
   PubMed Web of Science ®Google Scholar
• Hao J, Wang C, Yuan J, et al. A pro-inflammatory role of C5L2 in C5a-primed neutrophils for ANCA-induced activation. PloS One. 2013;8(6):e66305. PubMed PMID: 23785491; PubMed Central PMCID: PMC3681967.
   PubMed Web of Science ®Google Scholar
• Chen NJ, Mirtsos C, Suh D, et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature. 2007 Mar 08;446(7132):203–207. PubMed PMID: 17322907.
   PubMed Web of Science ®Google Scholar
• Bamberg CE, Mackay CR, Lee H, et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem. 2010 Mar 5;285(10):7633–7644. PubMed PMID: 20044484; PubMed Central PMCID: PMC2844210.
   PubMed Web of Science ®Google Scholar
• Kalant D, MacLaren R, Cui W, et al. C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem. 2005 Jun 24;280(25):23936–23944. PubMed PMID: 15833747.
   PubMed Web of Science ®Google Scholar
• Hartmann K, Henz BM, Kruger-Krasagakes S, et al. C3a and C5a stimulate chemotaxis of human mast cells. Blood. 1997 Apr 15;89(8):2863–2870. PubMed PMID: 9108406.
   PubMed Web of Science ®Google Scholar
• Daffern PJ, Pfeifer PH, Ember JA, et al. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med. 1995 Jun 1;181(6):2119–2127. PubMed PMID: 7760001; PubMed Central PMCID: PMC2192052.
   PubMed Web of Science ®Google Scholar
• Cochrane CG, Müller-Eberhard HJ. The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med. 1968 Feb 1;127(2):371–386. PubMed PMID: 4383923; PubMed Central PMCID: PMC2138443.
   PubMed Web of Science ®Google Scholar
• Williams TJ Vascular permeability changes induced by complement-derived peptides. Agents Actions. 1983 Aug; 13 (5–6): 451–455. PubMed PMID: 6195896.
   PubMedGoogle Scholar
• Humbles AA, Lu B, Nilsson CA, et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature. 2000 Aug 31;406(6799):998–1001. PubMed PMID: 10984054.
   PubMed Web of Science ®Google Scholar
• Kildsgaard J, Hollmann TJ, Matthews KW, et al. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Iimmunol. 2000 Nov 15;165(10):5406–5409. PubMed PMID: 11067891.
   PubMed Web of Science ®Google Scholar
• Mueller-Ortiz SL, Morales JE, Wetsel RA. The receptor for the complement C3a anaphylatoxin (C3aR) provides host protection against Listeria monocytogenes-induced apoptosis. J Iimmunol. 2014 Aug 1;193(3):1278–1289. PubMed PMID: 24981453; PubMed Central PMCID: PMC4122265. .
   PubMed Web of Science ®Google Scholar
• Wu MC, Brennan FH, Lynch JP, et al. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9439–9444. PubMed PMID: 23696668; PubMed Central PMCID: PMC3677481.
   PubMed Web of Science ®Google Scholar
• Coulthard LG, Woodruff TM. Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J Iimmunol. 2015 Apr 15;194(8):3542–3548. PubMed PMID: 25848071. .
   PubMed Web of Science ®Google Scholar
• Johswich K. Innate immune recognition and inflammation in Neisseria meningitidis infection. Pathog Dis. 2017 Mar 01;75(2). PubMed PMID: 28334203. DOI: 10.1093/femspd/ftx022.
   PubMed Web of Science ®Google Scholar
• Herrmann JB, Muenstermann M, Strobel L, et al. Complement C5a Receptor 1 exacerbates the pathophysiology of N. meningitidis sepsis and is a potential target for disease treatment. MBio. 2018 Jan 23;9(1). PubMed PMID: 29362231.
   Web of Science ®Google Scholar
• Johswich KO, McCaw SE, Islam E, et al. In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. PLoS Pathog. 2013;9(7):e1003509. PubMed PMID: 23935487; PubMed Central PMCID: PMC3723569.
   PubMed Web of Science ®Google Scholar
• Johswich KO, McCaw SE, Strobel L, et al. Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice. Infect Immun. 2015 Jan;83(1):354–363. PubMed PMID: 25368118; PubMed Central PMCID: PMC4288889.
   PubMed Web of Science ®Google Scholar
• Johswich KO, Gray-Owen SD. Modeling Neisseria meningitidis infection in mice: methods and logistical considerations for Nasal colonization and invasive disease. Methods Mol Biol. 2019;1969:149–168. PubMed PMID: 30877676.
   PubMedGoogle Scholar
• Seow V, Lim J, Iyer A, et al. Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a. J Iimmunol. 2013 Oct 15;191(8):4308–4316. PubMed PMID: 24043889.
   PubMed Web of Science ®Google Scholar
• Ember JA, Sanderson SD, Hugli TE, et al. Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am J Pathol. 1994 Feb;144(2):393–403. PubMed PMID: 7508686; PubMed Central PMCID: PMC1887151.
   PubMed Web of Science ®Google Scholar
• Asgari E, Le Friec G, Yamamoto H, et al. C3a modulates IL-1beta secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. 2013 Nov 14;122(20):3473–3481. PubMed PMID: 23878142.
   PubMed Web of Science ®Google Scholar
• Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol. 2004 Feb;4(2):133–142. PubMed PMID: 15040586.
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Brekke OL, Fung M, et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood. 2002 Sep 01;100(5):1869–1877. PubMed PMID: 12176911; eng.
   PubMed Web of Science ®Google Scholar
• Strobel L, Johswich KO. Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of Neisseria meningitidis infection. Sci Rep. 2018;8(1):10225.
   PubMedGoogle Scholar
• Krüger S, Eichler E, Strobel L, et al. Differential influences of complement on neutrophil responses to Neisseria meningitidis infection. Pathog Dis. 2018 Nov 1;76(8). PubMed PMID: 30476070.
   PubMed Web of Science ®Google Scholar
• Ember JA, Johansen NL, Hugli TE. Designing synthetic superagonists of C3a anaphylatoxin. Biochemistry. 1991 Apr 16;30(15):3603–3612. PubMed PMID: 2015217.
   PubMed Web of Science ®Google Scholar
• Otto M, Hawlisch H, Monk PN, et al. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J Biol Chem. 2004 Jan 2;279(1):142–151. PubMed PMID: 14570896.
   PubMed Web of Science ®Google Scholar
• Riedemann NC, Guo RF, Neff TA, et al. Increased C5a receptor expression in sepsis. J Clin Invest. 2002 Jul;110(1):101–108. PubMed PMID: 12093893; PubMed Central PMCID: PMC151030.
   PubMed Web of Science ®Google Scholar
• Li R, Coulthard LG, Wu MC, et al. C5L2: a controversial receptor of complement anaphylatoxin, C5a. Faseb J. 2013 Mar;27(3):855–864. PubMed PMID: 23239822.
   PubMed Web of Science ®Google Scholar
• Johswich K, Klos A. C5L2–an anti-inflammatory molecule or a receptor for acylation stimulating protein (C3a-desArg)? Adv Exp Med Biol. 2007;598:159–180. PubMed PMID: 17892211.
   PubMed Web of Science ®Google Scholar
• Zhang T, Garstka MA, Li K. The controversial C5a receptor C5aR2: its role in health and disease. J Immunol Res. 2017;2017:8193932. PubMed PMID: 28706957; PubMed Central PMCID: PMC5494583.
   PubMedGoogle Scholar
• Riedemann NC, Guo RF, Bernacki KD, et al. Regulation by C5a of neutrophil activation during sepsis. Immunity. 2003 Aug;19(2):193–202. PubMed PMID: 12932353.
   PubMed Web of Science ®Google Scholar
• Sonego F, Castanheira FV, Ferreira RG, et al. Paradoxical roles of the neutrophil in sepsis: protective and deleterious. Front Immunol. 2016;7:155. PubMed PMID: 27199981; PubMed Central PMCID: PMC4844928.
   PubMed Web of Science ®Google Scholar
• Mueller-Ortiz SL, Hollmann TJ, Haviland DL, et al. Ablation of the complement C3a anaphylatoxin receptor causes enhanced killing of Pseudomonas aeruginosa in a mouse model of pneumonia. Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L157–65. PubMed PMID: 16461429.
   PubMed Web of Science ®Google Scholar
• Dutow P, Fehlhaber B, Bode J, et al. The complement C3a receptor is critical in defense against Chlamydia psittaci in mouse lung infection and required for antibody and optimal T cell response. J Infect Dis. 2014 Apr 15;209(8):1269–1278. PubMed PMID: 24273177; PubMed Central PMCID: PMC3969542.
   PubMed Web of Science ®Google Scholar
• Busche MN, Stahl GL Role of the complement components C5 and C3a in a mouse model of myocardial ischemia and reperfusion injury. German Med Sci. 2010 Sep 8;8. PubMed PMID: 20930931; PubMed Central PMCID: PMC2940219. DOI:10.3205/000109.
   PubMedGoogle Scholar
• Mathieu MC, Sawyer N, Greig GM, et al. The C3a receptor antagonist SB 290157 has agonist activity. Immunol Lett. 2005 Sep 15;100(2):139–145. PubMed PMID: 16154494.
   PubMed Web of Science ®Google Scholar
• Martin U, Bock D, Arseniev L, et al. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J Exp Med. 1997 Jul 21;186(2):199–207. PubMed PMID: 9221749; PubMed Central PMCID: PMC2198980.
   PubMed Web of Science ®Google Scholar
• Quell KM, Karsten CM, Kordowski A, et al. Monitoring C3aR expression using a floxed tdTomato-C3aR reporter knock-in mouse. J Iimmunol. 2017 Jul 15;199(2):688–706. PubMed PMID: 28626064.
   PubMed Web of Science ®Google Scholar
• Wu F, Zou Q, Ding X, et al. Complement component C3a plays a critical role in endothelial activation and leukocyte recruitment into the brain. J Neuroinflammation. 2016 Jan 28;13:23. 10.1186/s12974-016-0485-y. PubMed PMID: 26822321; PubMed Central PMCID: PMC4731990.
   PubMed Web of Science ®Google Scholar
• Coureuil M, Bourdoulous S, Marullo S, et al. Invasive meningococcal disease: a disease of the endothelial cells. Trends Mol Med. 2014 Oct;20(10):571–578. PubMed PMID: 25178566.
   PubMed Web of Science ®Google Scholar
• Sauter RJ, Sauter M, Reis ES, et al. Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis. Circulation. 2018 Oct 16;138(16):1720–1735. PubMed PMID: 29802205; PubMed Central PMCID: PMC6202244.
   PubMed Web of Science ®Google Scholar
• Konar M, Granoff DM. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood. 2017 Aug 17;130(7):891–899. PubMed PMID: 28630122; PubMed Central PMCID: PMC5561903. .
   PubMed Web of Science ®Google Scholar
• Sprong T, Brandtzaeg P, Fung M, et al. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood. 2003 Nov 15;102(10):3702–3710. 10.1182/blood-2003-03-0703. PubMed PMID: 12881318.
   PubMed Web of Science ®Google Scholar
• Nabizadeh JA, Manthey HD, Steyn FJ, et al. The complement C3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4+ T cell responses. J Iimmunol. 2016 Jun 1;196(11):4783–4792. PubMed PMID: 27183625.
   PubMed Web of Science ®Google Scholar
• Wenderfer SE, Wang H, Ke B, et al. C3a receptor deficiency accelerates the onset of renal injury in the MRL/lpr mouse. Mol Immunol. 2009 Apr;46(7):1397–1404. PubMed PMID: 19167760; PubMed Central PMCID: PMC2697606.
   PubMed Web of Science ®Google Scholar
• Höpken UE, Lu B, Gerard NP, et al. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature. 1996 Sep 5;383(6595):86–89. PubMed PMID: WOS:A1996VF29500053; English.
   PubMed Web of Science ®Google Scholar
• Wessels MR, Butko P, Ma M, et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11490–11494. PubMed PMID: 8524789; PubMed Central PMCID: PMC40427.
   PubMed Web of Science ®Google Scholar
• Gu A, Zhang Z, Zhang N, et al. Generation of human CEACAM1 transgenic mice and binding of Neisseria Opa protein to their neutrophils. PubMed PMID: 20404914; PubMed Central PMCID: PMC2852402. eng PloS One. 2010;54:e10067.
   PubMed Web of Science ®Google Scholar
• Lappann M, Haagensen JA, Claus H, et al. Meningococcal biofilm formation: structure, development and phenotypes in a standardized continuous flow system. Mol Microbiol. 2006 Dec;62(5):1292–1309. PubMed PMID: 17121595. .
   PubMed Web of Science ®Google Scholar
• Weischenfeldt J, Porse B. Bone marrow-derived macrophages (BMM): isolation and applications. CSH Protoc. 2008 Dec 1 PubMed PMID: 21356739:2008. pdbprot5080. DOI:10.1101/pdb.prot5080
   PubMedGoogle Scholar
• Qu H, Magotti P, Ricklin D, et al. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol. 2011 Jan;48(4):481–489. PubMed PMID: 21067811; PubMed Central PMCID: PMC3014449.
   PubMed Web of Science ®Google Scholar